ScholarIQanswers from OpenAlex & ORCID
Solange Peters
ResearcherPublications, citations & collaboration network
Solange Peters is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Solange Peters have?
ScholarIQindexed works
Solange Peters has 930 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Solange Peters have?
ScholarIQcitation count
Solange Peters has 72,089 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Solange Peters?
ScholarIQh-index
Solange Peters has an h-index of 114 in OpenAlex.
What is the i10-index of Solange Peters?
ScholarIQi10-index
Solange Peters has an i10-index of 408 in OpenAlex.
What is the ORCID of Solange Peters?
ScholarIQorcid
The ORCID for Solange Peters is on the source record.
What is the OpenAlex record for Solange Peters?
ScholarIQopenalex
The OpenAlex for Solange Peters is on the source record.
What are the most-cited papers on Solange Peters?
ScholarIQmost cited works
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
Timothy A. Chan, Mark Yarchoan, Elizabeth M. Jaffee, Charles Swanton, Sergio A. Quezada, Albrecht Stenzinger, Solange Peters
Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
Matthew D. Hellmann, Luis Paz‐Ares, Reyes Bernabe Caro, Bogdan Żurawski, Sang‐We Kim, Enric Carcereny, Keunchil Park, Aurelia Alexandru, Lorena Lupinacci, Emmanuel de la Mora Jimenez, Hiroshi Sakai, István Albert, A. Vergnenègre, Solange Peters, Konstantinos Syrigos, Fabrice Barlési, Martin Reck, Hossein Borghaei, Julie R. Brahmer, Kenneth J. O’Byrne, William J. Geese, Prabhu Bhagavatheeswaran, Sridhar K. Rabindran, Ravi S. Kasinathan, Faith E. Nathan, Suresh S. Ramalingam
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Silvia Novello, Fabrice Barlési, Raffaele Califano, Tanja Čufer, Simon Ekman, Matteo Giaj Levra, Keith M. Kerr, Sanjay Popat, Martin Reck, Suresh Senan, G.V. Simo, Johan Vansteenkiste, Solange Peters
First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
David P. Carbone, Martin Reck, Luis Paz‐Ares, Ben Creelan, Leora Horn, Martin Steins, Enriqueta Felip, Michel M. van den Heuvel, Tudor–Eliade Ciuleanu, Firas Badin, Neal Ready, T. Jeroen N. Hiltermann, Suresh Nair, Rosalyn A. Juergens, Solange Peters, Elisa Minenza, John Wrangle, Delvys Rodríguez‐Abreu, Hossein Borghaei, George R. Blumenschein, Liza C. Villaruz, Libor Havel, Jana Krejčí, Jesus Corral Jaime, Han Chang, William J. Geese, Prabhu Bhagavatheeswaran, Allen C. Chen, Mark A. Socinski
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer
Solange Peters, D. Ross Camidge, Alice T. Shaw, Shirish M. Gadgeel, Jin Seok Ahn, Dong‐Wan Kim, Sai‐Hong Ignatius Ou, M. Pérol, Rafał Dziadziuszko, Rafael Rosell, Ali Zeaiter, Emmanuel Mitry, Sophie Golding, Bogdana Balas, Johannes Noé, Peter N. Morcos, Tony Mok